Exicure
Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on developing therapeutics utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to address a range of conditions, including neurological disorders, immuno-oncology, inflammatory diseases, and genetic disorders. Its lead drug candidate, AST-008, is currently undergoing Phase 1b/2 clinical trials for advanced solid tumors. Additionally, Exicure is advancing XCUR-FXN, an SNA-based therapeutic for Friedreich’s ataxia in preclinical trials, and XCUR17, which targets the mRNA encoding interleukin 17 receptor alpha. The company has established collaborations with Allergan Pharmaceuticals to develop SNA-based treatments for hair loss and with DERMELIX, LLC for research and commercialization efforts related to netherton syndrome. Founded in 2011, Exicure is developing a new class of immunomodulatory and gene silencing drugs that enhance the delivery and efficacy of nucleic acid therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.